Accession Number : ADB159073
Title : Effective Evaluation of Intravenous Ribavirin Therapy of Epidemic Hemorrhagic Fever by a Prospective, Double-Blind, Concurrent, Randomized and Placebo-Controlled Design.
Descriptive Note : Final rept. 1 Nov 85-31 Oct 90,
Corporate Author : HUBEI MEDICAL COLL (CHINA) VIRUS RESEARCH INST
Personal Author(s) : Hsiang, Chin-Min
Report Date : 01 DEC 1990
Pagination or Media Count : 36
Abstract : A prospective, randomized, double-blind, concurrent, placebo controlled, clinical trial of intravenous ribavirin was conducted in patients with epidemic hemorrhagic fever in Wuchang, Hubei, the People's Republic of China. Comparability of treatment groups at baseline was demonstrated. Mortality was significantly reduced (a seven fold decrease in risk of death) among ribavirin treatmented patients when comparisons were adjusted for baseline risk estimators of mortality (p=0.01, 2 tailed). Hemorrhagic fever with renal syndrome typically consists of five consecutive, but frequently overlapping, clinical phases. Occurrence of the oliguric and hemorrhage phases was associated with severity of clinical disease in the placebo group. Ribavirin therapy resulted in a significant reduction in (1) the risk of entering the oliguric phase, (2) serum creatinine levels, (3) duration of hypertension, (4) the risk of experiencing hemorrhage, and (5) death. The only ribavirin related side effect was anemia. Which was fully recovered following completion of therapy.
Descriptors : ANEMIAS, BASE LINES, BLOOD SERUM, CHINA, CLINICAL MEDICINE, CONTROL, CREATININE, DEATH, DISEASES, EPIDEMIOLOGY, HEMORRHAGE, HEMORRHAGIC FEVERS, HYPERTENSION, KIDNEYS, PHASE, PLACEBOS, RISK, SIGNS AND SYMPTOMS, THERAPY, TIME.
Subject Categories : Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE